STOCK TITAN

Inogen (NASDAQ: INGN) CFO logs RSU vesting, share tax withholdings

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Inogen Inc EVP, CFO & Treasurer Michael J. Bourque reported multiple equity transactions. He acquired common stock through the vesting and exercise of restricted stock units on March 1, 2026, along with additional stock awards, and had shares withheld to satisfy tax obligations.

Several restricted stock unit awards converted into common stock at a stated price of $6.10 per share for tax purposes, with disposals labeled as tax-withholding transactions rather than open-market sales. After these transactions, he directly held 94,596 shares of Inogen common stock and 39,000 restricted stock units, each unit representing a contingent right to one share.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bourque Michael J.

(Last) (First) (Middle)
C/O INOGEN, INC.
500 CUMMINGS CENTER, SUITE 2800

(Street)
BEVERLY MA 01915

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Inogen Inc [ INGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, CFO & Treasurer
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/01/2026 A 874(1) A $6.1 50,020 D
Common Stock 03/01/2026 M 25,000 A $0 75,020 D
Common Stock 03/01/2026 F 9,338(2) D $6.1 65,682 D
Common Stock 03/01/2026 A 28,875(3) A $0 94,557 D
Common Stock 03/01/2026 F 10,615(4) D $6.1 83,942 D
Common Stock 03/01/2026 M 17,007 A $0 100,949 D
Common Stock 03/01/2026 F 6,353(2) D $6.1 94,596 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (5) 02/27/2026 A 39,000 (6) (6) Common Stock 39,000 $0 39,000 D
Restricted Stock Unit (5) 03/01/2026 M 25,000 (7) (7) Common Stock 25,000 $0 25,000 D
Restricted Stock Unit (5) 03/01/2026 M 17,007 (8) (8) Common Stock 17,007 $0 34,013 D
Explanation of Responses:
1. Shares acquired through the Company's 2014 Employee Stock Purchase Plan.
2. The reported shares were withheld to cover the reporting person's tax withholding liability in connection with a portion of a time-based restricted stock unit award that vested on March 1, 2026.
3. The reported securities represent shares earned and vested on March 1, 2026 based on achievement of the financial performance conditions for the 2025 fiscal year that were approved as part of the 2023 performance-based restricted stock unit award granted on March 4, 2024.
4. The reported shares were withheld to cover the reporting person's tax withholding liability in connection with the 2023 performance-based restricted stock unit award granted on March 4, 2024 and vested on March 1, 2026.
5. Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
6. Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2027 (the "2027 Vesting Commencement Date"), and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2027 Vesting Commencement Date.
7. 1/3rd of the restricted stock units vested on March 1, 2025 (the "2025 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2025 Vesting Commencement Date.
8. 1/3rd of the restricted stock units vested on March 1, 2026 (the "2026 Vesting Commencement Date"), and subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the 2026 Vesting Commencement Date.
/s/ Mary Wright, as Attorney-in-Fact 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Inogen (INGN) EVP and CFO Michael Bourque report in this Form 4 filing?

Michael Bourque reported equity awards and related share movements, mainly from restricted stock units. On March 1, 2026, units vested and converted into common stock, and some shares were withheld to cover tax liabilities, updating his direct holdings in Inogen.

How many Inogen (INGN) common shares does the CFO hold after these transactions?

After the reported transactions, Michael Bourque directly holds 94,596 shares of Inogen common stock. This figure reflects stock received from restricted stock unit vesting and exercises, offset by shares withheld to satisfy tax withholding obligations tied to those awards.

What restricted stock unit position did the Inogen (INGN) CFO report?

The filing shows Michael Bourque holding 39,000 restricted stock units. Each unit represents a contingent right to receive one share of Inogen common stock, subject to vesting conditions and continued service requirements described in the accompanying vesting footnotes.

Were any of the Inogen (INGN) CFO’s share disposals in this Form 4 open-market sales?

The disposals reported use transaction code F, indicating shares were delivered to cover exercise price or tax liabilities. Footnotes clarify these shares were withheld for tax withholding obligations, not sold in open-market transactions to third-party buyers.

What vesting conditions apply to the Inogen (INGN) restricted stock units reported?

Footnotes state certain restricted stock units vest in thirds on specific March 1 vesting commencement dates, with remaining thirds vesting annually thereafter. Vesting is conditioned on the reporting person’s continued service with the company over the stated vesting schedule.

Did the Inogen (INGN) Form 4 include performance-based restricted stock units?

Yes. A footnote explains some reported securities were earned and vested on March 1, 2026, based on achievement of financial performance conditions for the 2025 fiscal year under a 2023 performance-based restricted stock unit award granted March 4, 2024.
Inogen Inc

NASDAQ:INGN

INGN Rankings

INGN Latest News

INGN Latest SEC Filings

INGN Stock Data

168.59M
23.85M
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BEVERLY